BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, January 11, 2025
See today's BioWorld
Home
» Deciphera gains $52M in muscle to move lead assets to next level
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Deciphera gains $52M in muscle to move lead assets to next level
June 2, 2017
By
Marie Powers
No Comments
On the eve of the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Deciphera Pharmaceuticals LLC disclosed a $52 million series C financing to advance lead candidates DCC-2618 and DCC-3014 beyond phase I.
BioWorld
